Physician profile
Allison A Angott
NPI 1972579944
$5,212.09
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $763 · 2021: $1,533 · 2022: $1,485 · 2023: $456 · 2024: $51.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $978.76 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $539.09 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $515.67 | 2020-2023 | Fasenra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.15 | 2019-2022 | |
| Pfizer INC. | $289.44 | 2019-2023 | |
| Abbvie INC. | $262.86 | 2020-2024 | Ubrelvy |
| Glaxosmithkline, LLC. | $256.01 | 2019-2024 | Arexvy, Shingrix |
| Lilly USA, LLC | $233.27 | 2019-2023 | Mounjaro |
| Hikma Pharmaceuticals USA | $224.99 | 2020-2023 | Kloxxado, Ryaltris, Mitigare |
| Merck Sharp & Dohme LLC | $185.44 | 2019-2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $170.57 | 2021-2023 | |
| Amarin Pharma, INC. | $157.18 | 2020-2022 | |
| Abbott Laboratories | $127.95 | 2019-2023 | Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $119.15 | 2019 | |
| Esperion Therapeutics, INC. | $118.87 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Angott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.